Chris Brawley

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

Medicine, Oncology, Urology +14

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Urology +13

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

N.W. Clarke, Amin Ali, Fiona C. Ingleby et al. · Annals of Oncology · 2019 · 398 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Alex Hoyle, Adnan Ali, Nicholas D. James et al. · European Urology · 2019 · 205 citations · Full text

Medicine, Oncology, Urology +12

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer

Adnan Ali, Alex Hoyle, Áine Haran et al. · JAMA Oncology · 2021 · 137 citations · Full text

Medicine, Oncology, Radiation Oncology +17